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Antibiotics have been used as the primary treatment for bacterial infections since 
the 1940’s.  Unfortunately, the use and misuse of antibiotics has led to the proliferation of 
antibiotic-resistant bacteria and resulted in the loss of antibiotic efficacy.  Alternative 
strategies for fighting bacterial infections are needed to preserve our ability to cure 
bacterial infections.  One strategy that has shown promise in in vitro and animal studies is 
the anti-virulence approach.  Unlike the traditional antibiotic approach, which focuses on 
inhibiting bacterial growth, the anti-virulence approach focuses on disrupting bacteria 
pathogenesis.  Inhibition of bacteria pathogenesis results in a less invasive infection that 
can be cleared by the innate immune system.  Anti-virulence compounds have proven to 
be less susceptible to resistance development, which suggests their potential for long term 
therapeutic development.  Unfortunately, only a limited number of anti-virulence 
compounds have been discovered and none have made it to the clinical setting.  One goal 
of this research was to develop a new biological screening method to identify new anti-
virulence compounds, particularly aimed at treating Gram-positive bacterial infections. 
In Gram-positive bacteria such as Staphylococcus aureus, virulence is regulated 
by the accessory gene regulator (agr) system.  The agr system is a quorum sensing 
system activated by a small cyclic peptide known as AIP.  The inhibition of the quorum 
sensing system results in the inhibition of bacterial virulence, making this system an ideal 
target for anti-virulent therapeutics.  With this research, we developed a liquid 
chromatography-mass spectrometry (LC-MS) method to measure the activity of potential 
quorum sensing inhibitors based on their ability to inhibit AIP production.  Prior to 
applying this method, it was necessary to develop approaches to detect the AIPs of 
interest directly from bacterial cultures, and to elucidate the structures of unknown AIPs.  
Mass spectrometry was employed to achieve both of these goals, and we detected eight 
AIPs directly from bacterial cultures.  In addition, we elucidated the structures of two 
previously unidentified AIPs, that of Listeria monocytogenes and Staphylococcus 
saprophyticus.  The newly developed assay was then utilized to identify a new quorum 
sensing inhibitor, 8-oxotetrahydrothalifendine, which was shown to act as a quorum 
sensing signal biosynthesis inhibitor in Staphylococcus aureus.  Future experiments will 
involve employing the newly developed assay to screen natural product extract libraries 
for novel quorum sensing inhibitors.   
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CHAPTER I 
A BRIEF HISTORY OF ANTIBIOTICS, THE DEVELOPMENT OF ANTIBIOTIC 
RESISTANCE, AND HOPE FOR THE FUTURE 
1.1 History of Antibiotics 
 The commercialization of antibiotics was undoubtedly one of the greatest 
advancements of modern medicine [1].  These powerful therapeutic agents has saved 
countless lives throughout history, and forever changed our approach to treating 
microbial infections.  In this brief summary, we will discuss the key events in science 
history that helped bring about the dawning antibiotic era, explore the promise of the 
"Golden Age" of antibiotic drug discovery, and investigate recent decades of discovery 
void.    
1.1.1 The Dawning of the Antibiotic Era 
 The existence of bacteria was first recognized in the late 1600's [2]. However, it 
was not until two centuries later that the connection between bacteria and disease was 
observed [2, 3].  Bacteria have since been associated with some of the worst epidemics in 
human history, including the bubonic plague, syphilis and tuberculosis [3].  Mankind has 
spent an  immense amount of time and resources attempting to combat these deadly 
infectious, and up until the early 1900's a majority of the progress made was due to 
preventative measures [3].  In 1909, Paul Ehrlich discovered the first antimicrobial 
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agent used specifically to cure a bacterial infection.  Ehrlich is accredited for discovering 
the drug salvarsan, a highly effective treatment for syphilis.  Prior to this discovery, 
syphilis was recognized as incurable, epidemic disease that was highly prevalent in 
Europe and North America starting the in late 1400's.  While salvarsan's mode of action 
is still unknown, it was the most frequently prescribed drug up to the 1940's and laid the 
ground work for discovery of new antimicrobials. 
 Another early antimicrobial that helped to usher in the antibiotic era was the 
sulfanilamide drug prontosil [1].  Prontosil was first synthesized by two chemists at 
Bayer, Josef Klarer and Fritz Mietzsch [1] in 1935, and was identified by Gerhard 
Domagk as a treatment for a number of diseases.  Once the effectiveness of this class of 
compounds to fight bacterial infections was observed, several derivatives became 
available [1].  Sulfanilamides proved to be an effective treatment for a variety of bacterial 
infections, including the streptococcal infections commonly associated with burns and 
childbirth in the late 1800's [2].  One report in 1846 put the maternal mortality rate at 
11.4% for women delivering in the maternity ward of a prominent clinic in Vienna.  
While changes in general hygiene helped reduced this number down to 3%, it was until 
the introduction of sulfanilamide drugs that this number became much more on par with 
today's standards of  <0.02%.  Following the introduction of sulfanilamides the mortality 
rate of acute meningococcal meningitis decreased from 70-90% to approximately 10% 
[4]. 
 While salvarsan and protosil both played significant roles leading to the 
development of modern antibiotic treats, Penicillin is the most widely recognized as the 
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drug that began the antibiotic era.  In 1928, Alexander Fleming observed that a colony of 
Penicillium rubrum was capable of causing  co-cultured Staphlyococcus cells to lyse [5].  
He further went on to investigate the antibacterial characteristics of the P. rubrum filtrate, 
and discovered it was very potent against a variety of bacteria [5].  Fleming spent the 
following decade attempting to isolate the compound responsible for the observed 
antibacterial activity. However, his efforts were unsuccessful [1].  Fortunately, in 1940, 
Howard Florey and Ernest Chain developed a method for purifying penicillin in 
significant quantities and showed its efficacy with in vivo studies [6].  Penicillin was 
successfully used for the first time United States in 1942 [7], and by 1945, over 650 
billion units of penicillin were being produced monthly [7].  Penicillin quickly surpassed 
salvarsan as the most frequently prescribed drug [1], and has been attributed to saving 
over 2 million lives during World War II.   
 For their significant contributions to society Ehrlich, Domagk, Fleming, Florey, 
and Chain were all award Nobel Prizes in Physiology or Medicine.  Ehrlich received the 
1908 Nobel Prize, Domagk was award the 1939 Nobel Prize, and Fleming, Florey, and 
Chain received the 1945 Nobel Prize [8].  Each of these key discoveries played a crucial 
role in laying the groundwork for the antibiotic era and was responsible for saving 
countless lives throughout history. 
1.1.2 The Golden Age of Antibiotics 
 The promise brought about by the discovery of the first antibiotics led to a surge 
of research effort into discovery of new antimicrobial compounds.  The time period 
between the 1940’s and the early 1970’s saw the greatest increase of new classes of 
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antibiotics in history, therefore has been dubbed the "Golden Age" of antibiotic 
discovery.  This section is dedicated to exploring some of the key discoveries made 
during this time-period. 
 The discoveries of salvarsan, protosil, and penicillin not only provided promise 
the bacterial infections could be efficiently cured, but also provided the basic framework 
for discovering new antibiotics.  After learning of Fleming's serendipitous discovery of 
penicillin from a P. rubrum fungal isolate, Selman Abraham Waksman turned to 
Actinomycetes cultures hoping to discover antibiotics that were even more promising.  
This decision paid off in the early 1940's, when Waksman and his student, Albert Schatz, 
discovered streptomycin.  Streptomycin was a new class of antibiotic, capable of 
inhibiting the growth of both Gram-positive and Gram-negative pathogens [9].  The most 
interesting activity of streptomycin was its ability to fight tuberculosis infections. 
 During the 1880's, tuberculosis was responsible for one in five deaths in England, 
and by 1937 it was the leading cause of death in the United States.  In 1945 streptomycin 
delivered on its promise as a cure for this deadly infection, and cured its first patient with 
a pulmonary tuberculosis infection.  While streptomycin is most notably recognized for 
its success against tuberculosis, it was also an effective treatment for a number of other 
diseases including: leprosy, meningitis, empyema, pneumonia, gonorrhea, tularaemia and 
glanders [10].  For the discovery of streptomycin, Waksman was award the 1952 Nobel 
Prize for Physiology and Medicine [8].  
 The first broad-spectrum antibiotic identified was chloramphenicol.  This 
antibiotic was originally isolated from Streptomycin venezuelea by Paul Burkholder, but 
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became the first antibiotic to be fully synthesized [10, 11].  Chloramphenicol was most 
widely recognized for its ability to cure typhus, an infection caused by Rickettsia 
prowazeki [12].  This devastating disease can be found worldwide and has been 
responsible for a number of epidemics throughout history [12].  The success of 
chloramphenicol was soon overshadowed by its devastating side effects and its use began 
to drop drastically.  Fortunately, by this time Benjamin Duggar had identified 
aureomycin, the second antibiotic with broad-spectrum capabilities.  Aureomycin proved 
to be an effective treatment of typhus without the life threatening side effects. 
 The time period between 1940 and 1970 brought about the discovery of 12 new 
classes of antibiotics [4] and provided hope for those suffering from bacterial infections.  
Some of the other key discoveries during this time include: erythromycin (1952), 
vancomycin (1956) and genamicin (1963) [10].  Unfortunately, the introduction of 
trimethoprim in 1968 proved to be the end of the Golden Age, and no new classes of 
antibiotics were introduced until the year 2000 [4, 13]. 
1.1.3 The Current Void  
 Changes in regulation and decreasing interest in antibiotics by the pharmaceutical 
industry have led to reduced antibiotic innovation.  A recent review by Lynn Silver 
accentuates this problem by pointing out that though we have recently introduced new 
classes of antibiotics to the market, these classes were all discovered decades earlier and 
no new class of antibiotic has been discovered since 1987 [14].   The lack of new 
antibiotic classes, however, does not mean a lack in new therapeutic agents.  There has 
been a continuing flow of new antibiotics introduced since the 1970's, however, these 
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have all been members of previously identified classes or modifications of existing 
therapeutics [1].  Unfortunately, this pipeline, too, has become depleted.  Between 
the1983 and 2002 there was 56% drop in new antibiotics approved by the Food and Drug 
Administration [4].   
1.2 Antibiotic Resistance - The End of the Miracle Cure  
During his Nobel lecture in 1945, Alexander Fleming forewarned that improper 
use of penicillin could result in penicillin-resistant bacteria [8].  Over half a century later, 
resistance has been discovered to every major class of antibiotic (Figure 1).  In 2013, the 
Centers for Disease Control and Prevention (CDC) released a report on the threat of 
antibiotic resistance that revealed over 2 million illnesses are a direct result of antibiotic 
resistant microorganisms in the United States each year.  This report also indicated that 
over 23,000 deaths occur each year in the United States attributable to these threats.  This 
section will discuss some of the factors that have resulted in the current antibiotic 
resistant epidemic and explore some the mechanism of resistance utilized by bacteria. 
1.2.1 Foundations of Resistance 
 The misuse of antibiotics plays a role in current antibiotic resistance epidemic.  In 
2008, it was estimated that over 55% of all the antibiotics prescribed for acute respiratory 
infections in the United States were unnecessary [15].  The majority of these infections 
are viral, not bacterial, and therefore are unaffected by the use of antibiotics [16].  When 
a patient is given unnecessary antibiotics, their natural microflora can adapt to the 
presence of the antibiotic and establish resistance.  If the patient then develops an actual 
bacterial infection, the resistance genes can be transferred to the pathogen, resulting in an 
7 
antibiotic resistant bacteria pathogen.  While healthcare professionals may be responsible 
for prescribing unnecessary antibiotics, patients have also attributed to the rise in 
antibiotic resistance by not proper taking antibiotics that have been appropriately 
prescribed.  When a patient takes the incorrect dose, misses a dose, or prematurely stops 
treatment, the antibiotic is unable to effectively clear the infection, and the remaining 
bacteria are exposed to low levels of the antibiotic.  This results in the bacterial pathogen 
surviving long enough to develop a resistance to the antibiotic.  In either of the cases 
described above, the patient can then transfer the antibiotic bacteria to other members 
within the community, thus perpetuating the problem. 
  
 While the direct misuse of antibiotics have aided in the spread of antibiotic 
resistance, people can also be exposed to antibiotic resistant bacteria in the food they 
 
Figure 1.  Timeline of Antibiotic Introduction and the Identification of Resistance. 
Above the timeline shows the year that the antibiotic was introduced for clinical 
use, and below the timeline shows the year that resistance was identified.  Figure 
is based on a previously published figure by the Centers for Disease Control and 
Prevention [17]. 
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consume.  In 2011, it was estimated the 80% of the antibiotics sold in the United States 
went to the agriculture industry [18].  These antibiotics are used primarily for disease 
management (prevention, treatment, and control) and growth promotion [19].  This 
overexposure to antibiotics results in the cultivation of antibiotic resistant bacteria in 
livestock that can be transferred to the human consumer [18, 20-22].  Antibiotics are also 
excreted by the animals and their manure is then used as fertilizer on crops [23].  This 
low level of antibiotics results in the development of resistance by plant and soil bacteria 
[22, 23].  The crops are then harvested for either animal feed [24] or human 
consummation [18], resulting in the continual spread of antibiotic resistance.   
1.2.2 Mechanisms of Resistance 
 There are three primary mechanisms of antibiotic resistance utilized by bacteria: 
modification of the antibiotic, modification of the target effected by the antibiotic, and 
removal of the antibiotic from the cell.  The modification of the antibiotic typically 
occurs though enzymatic action.  Edward Abraham and Ernest Chain published one of 
the first records of antibiotic resistance in 1940, two years prior to its first medical use in 
the United States, in which they noted an enzyme produced by Balantidium coli could 
deactivate penicillin [25].  This was the first of around 1000 β-lactamases enzymes to be 
identifed [22].   β-lactams, such as penicillin, kill bacterial cells by inhibiting cell wall 
biosynthesis of the transpeptidase, penicillin-binding protein.  The resulting unstable cell 
wall causes the bacterial cells to lyse.  The β-lactam ring (Figure 2) is the primary  
active site for this class antibiotic.  β-lactamases hydrolyze this ring and render the  
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antibiotic inactive [26].  However, advances in antibiotic research resulted in the 
development of β-lactams specifically designed to slow down the enzymatic resistance 
utilized by the bacteria.  An example of a β-lactamase resistant antibiotic is methicillin 
(Figure 3).  Unfortunately, within one year after the release of methicillin, methicillin-
resistance had been identified [27].  However, this resistance was not a modification of a 
β-lactamase enzyme, but was a modification of the penicillin-binding protein.  
Modification of the target protein is the mechanism of resistance utilized by methicillin-
resistant Staphylococcus aureus [26, 27], one of the most prevalent antibiotic resistant 
bacteria pathogens in the world.  Modification of the penicillin-binding protein structure 
reduces the affinity of methicillin to the protein and renders methicillin inactive.   
Modification of the antibiotic or of the antibiotic’s target is utilized by a variety of Gram-
positive and Gram-negative bacteria as means of antibiotic resistance.  
 
Figure 2.  Structure of Penicillin 
Molecular structure of Penicillin G with the signature β-lactam ring drawn in red.  
The β-lactam ring is the active site for all antibiotics of the β-lactam class. 
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Figure 3.  Structure of Methicillin 
Molecular structure of methicillin with the methoxy groups drawn in red.  The 
addition of the two methoxy groups results in methicillin being less susceptible to 
β-lactamase modification. 
 
 The third mechanism of antibiotic resistance is the removal of the antibiotic from 
the cell.  If the antibiotic is unable to reach a lethal concentration within the cell, the 
antibiotic will be ineffective at killing the bacteria.  The machinery used to remove 
antibiotics from the cell is known as an efflux pump.  There are five families of bacterial 
efflux pumps: the resistance-nodulation-division (RND) family, the major facilitator 
superfamily (MFS), the ATP (adenosine triphosphate)-binding cassette (ABC) 
superfamily, the small multidrug resistance (SMR) family, and the multidrug and toxic 
compound extrusion (MATE) family [28].  Pumps from the RND, MFS, SMR, and 
MATE families use an ion exchange force (H
+
 or Na
+
) to remove substrates from within 
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the cell.  The ABC family utilizes the hydrolysis of ATP to active the pump [26].  Pumps 
can either be substrate specific, such as tetracycline pumps, or very generic.  This allows 
for a very broad range of antibiotic resistance [26, 28].  Often times efflux pumps will be 
over expressed as means of antibiotic resistance, allowing the cell to remove the 
antibiotic in a more efficient manner.  Efflux pumps are found in a variety of Gram-
positive and Gram-negative bacteria including Escherichia coli, Neisseria gonorrhoeae, 
Pseudomonas aeruginosa, Salmonelle typhimurium, and Staphylococcus aureus [28]. 
1.3 Looking to the Future 
 The discovery and development of antibiotics has undoubtedly been one the 
greatest advance in modern medicine, unfortunately it was not without a cost. The rise of 
antibiotic resistant bacteria has limited the efficacy of once powerful antibiotics, and 
created an urgent need for the development of novel therapies.  While discovering new 
antibiotics may provide some relief in the current antibiotic resistance epidemic, history 
shows this may not be a long term solution.  Even with good antibiotic stewardship, 
resistance may be inevitable.  In a study conducted by Bhullar et al., antibiotic resistance 
was identified in a strain of bacteria that had been geographically isolated for 4 million 
years [29].  Indicating resistance is an inherent characteristic of bacteria, and while 
misuse of antibiotics may accelerate the predominance of resistance, it is not the root 
cause. 
 One approach for combating antibiotic resistant bacteria is combination therapy.  
This strategy has been successfully utilized to counter β-lactamase resistance with drugs 
like Augmentin and Primaxin, which combine a β-lactam antibiotic with a β-lactamase 
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inhibitor.  Another combination approach that has proved effective in the laboratory, but 
has yet to reached the clinic, is the inhibition of bacterial efflux pumps.  Inhibition of the 
efflux pumps would result in the bacteria being unable to remove the antibiotic [30, 31].  
While these types of approaches are promising, they still exert selective pressure that 
leads to the development of resistance.  Antibiotics will always play a role in combating 
bacterial infections, but new strategies for augmenting their use are needed.  One option 
would be to inhibit nonessential bacterial cell function that cause stress to the host.  This 
would allow the host’s innate immune system to concentrate its efforts on clearing the 
bacterial infection, instead of repairing the damage bacteria cause.  Inhibition of bacteria 
pathogenesis is the foundation of the anti-virulence approach that is the focus of the 
studies presented here.  Chapter II is dedicated to understanding ways to inhibit 
pathogenesis in a variety of Gram-positive bacteria.  The knowledge gained by the 
studies described in Chapter II supports the development of a novel biological assay 
described in Chapter III, which will permit the efficient screening for new compounds 
capable of targeting bacterial infections.  The efficient screening method is then utilized 
in Chapter IV to identify a compound from a medicinal plant extract that targets bacterial 
pathogenesis by an unusual mode of action. 
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CHAPTER II 
IDENTIFICATION AND QUANTIFICATION OF AUTO-INDUCING PEPTIDES 
2.1 Introduction 
 According to the Centers for Disease Control and Prevention, antibiotic resistant 
bacteria are responsible for over 2 million illnesses and 23,000 deaths in the United 
States each year. These infections result in an estimated economic impact of over $55 
billion dollars.  With an ever-increasing emergence in antibiotic resistance and a 
depleting antibiotic discovery pipeline, it has become imperative to find new approaches 
for fighting these costly infections.  One promising strategy for combating antibiotic 
resistant infections is to target bacterial pathogenesis, the so-called “anti-virulence” 
approach [32].  This strategy has the hypothetical advantages of limiting the evolution of 
widespread drug resistance, facilitating the development of host immune responses, and 
avoiding negative impacts on the normal microbial flora [33-36].  
 In Gram-positive bacteria, virulence is regulated by a quorum sensing system 
known as the accessory gene regulator (agr) system (Figure 4).  The agr system is 
activated by a small cyclic peptide known as autoinducing peptide or AIP.  The agr 
system has previously been described in detail [37-39].  In short, it consists of four 
primary components, AgrBDCA.  AgrD is a propeptide, which is processed into AIP by 
the membrane peptidase AgrB and transferred through the cytoplasmic membrane.  AIP 
then binds to the membrane-bound histidine kinase, AgrC, resulting in the 
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phosphorylation of the AgrA response regulator, which in turn leads to the activation of 
two RNA promoters P2 and P3.  The P2 and P3 promoters activate transcription of 
RNAII and RNAIII, respectively.  RNAII transcription leads to production of AgrBDCA, 
while RNAIII transcription regulates a variety of cellular functions, including, most 
importantly, the activation of virulence factors.   Each species of bacteria produces a 
unique agr system, and therefore regulated by a unique AIP.  Some species of bacteria 
have developed further diversity and express multiple agr types.  For example, strains of 
S. aureus are divided into four agr types (I, II, III and IV).  Each type is activated by a 
unique AIP (I, II, III and IV). 
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Figure 4.  Schematic of the Agr System. 
The agr locus is comprised of two divergent transcripts called RNAII and RNAIII 
driven by the P2 and P3 promoters, respectively [39, 40].  The core machinery of 
the agr system is encoded by the four genes (agrBDCA) of the RNAII operon.  
The propeptide, AgrD, is transformed into the system regulating cyclic peptide, 
AIP.  AIP binds to the AgrC receptor, resulting in the phosphorylation of the 
AgrA response regulator and the activation of the P2 and P3 promoters [39, 40]. 
 
AIP is both an activator of the agr system and a direct output.  Thus, this 
molecule is a promising biomarker for monitoring agr system activity.  If the activity of 
the agr system is reduced, i.e. by the addition of an inhibitor, an associated decrease in 
AIP production should be observed.  An important goal of this study was to develop 
quantitative approaches for measuring potency of AIP inhibition by relying on detection 
of AIP. 
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 Until very recently, AIP detection has been a cumbersome task requiring 
extensive sample cleanup [41-44].  One method was previously developed that allowed 
direct measurement of AIPs from several species of Gram-positive bacteria using matrix-
assisted laser desorption ionization mass spectrometry (MALDI) [45].  However, this 
approach is inherently limited to qualitative assessments (identification but not 
quantification).  Another approach demonstrated recently by our laboratory could be used 
to quantify AIP production in bacterial cultures from Staphylococcus aureus, which 
produce AIP at relatively high concentrations (~10 µM) [43, 46].   This method was not, 
however, effective for identification or quantitative assessments by other bacteria, i.e. S. 
epidermidis and L. monocytogenes, presumably because of low levels of AIPs produced 
by these strains.   
 Quantitative measurements of AIP production require knowledge of AIP 
structures; thus, AIP identification was a second goal of this study. The agr system genes 
have been fully sequenced for a number of Gram-positive bacteria [39], and AIP 
sequences have been predicted for these organisms [39].  However, AIP structures have 
yet to be confirmed for the majority of Gram-positive bacterial strains (Table 1).  A 
previous study from our laboratory showed that in the case of S. epidermidis [44], there 
was lack of agreement between predicted and measured structures of AIP.  Thus, it is 
important to follow up predictions of AIP structure with experimental verification. 
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Table 1.  Bacteria Species Containing Agr Systems  
 
*
AIP sequences that have been previously identified, bold sequences are AIP 
sequences confirmed in this study, yellow highlighted sequences are AIP 
sequences identified in this study.  All other AIP sequences are predicted AIP 
sequences based on gene transcription.  Red residues are the identified/predicted 
residue that forms the thiolactone or lactone ring with the c-terminus [39]. 
 
 Recently, a new generation of high resolving power hybrid mass spectrometers 
has been developed that employs a combination of quadrupole and Orbitrap mass 
analyzers.  Relying on the exceptional sensitivity and mass accuracy of this new mass 
spectrometer design, in combination with the outstanding chromatographic resolution 
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achievable with ultra-high performance liquid-chromatography (UHPLC), we developed 
a method to directly identify, detect, and quantify AIP in the crude growth media of 
multiple Gram-positive bacteria.  Using our newly developed method, we compared the 
potency of known quorum sensing inhibitor ambuic acid across multiple strains of Gram-
positive bacteria.  This study is the first to demonstrate the application of a mass 
spectrometry-based approach for determining IC50 values for AIP inhibition. 
2.2 Materials and Methods 
2.2.1 Instrumentation 
 Optical density readings were performed using a Synergy H1 Mutli-Mode Reader 
(Biotek Instruments, Inc., Winooski, VT).  Unless otherwise stated, liquid 
chromatography-mass spectrometry (LC-MS) analyses were performed using an Aquity 
ultra-high performance liquid chromatography (UPLC) system (Waters Corporation, 
Milford, MA) coupled to a Q Exactive Plus Hybrid Quadrupole-Orbitrap mass 
spectrometer (Thermo Fisher Scientific, Waltham, MA).  Unless otherwise stated, all 
solvents used for chemical analyses were purchased from Thermo Fisher Scientific 
(Waltham, MA) 
2.2.2 Bacterial Strains, Media and Growth Conditions 
 Bacterial strains used in this study are listed in Table 2.  All strains were provided 
by the Horswill lab at University of Iowa, Iowa City, Iowa.   Strains AH335 and LS1 
were maintained in Brain Heart Infusion broth (Teknova, Hollister, CA).  All other 
strains were maintained in Tryptic Soy broth (Sigma Aldrich, St. Louis, MO). 
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Table 2.  Bacteria Strains 
Species Strain Number Description 
Enterococcus faecalis AH3335 ATCC Strain 47077/ OG1RF 
Listeria monocytogenes LS1 EGDe serotype 1/2a [47] 
Staphylococcus aureus AH1263 WT USA300 LAC MRSA (agr type I) 
 AH2623 USA100 (agr type II) 
 AH759 UAMS-1 Clinical isolate (agr III) [48] 
Staphylococcus epidermidis 4804 Clinical isolate (agr type I) [44] 
 5183 Clinical isolate (agr type II) [44] 
 5794 Clinical isolate (agr type III) [44] 
Staphylococcus lugdunensis AH2160 N920 143 (agr type I) 
Staphylococcu saprophyticus AH2776 ATCC 15305  
 
2.2.3 Identification and Detection of Auto-Inducing Peptides 
Single isolated colonies of each strain were grown overnight at 37 °C.  Overnight 
cultures were then diluted 1:200 (bacterial culture:broth) and shaken for at least 16 hr at 
200 rpm and 37 °C.  Cells were pelleted by centrifugation at 6,000 × g for 5 min and 
removed by 0.22-μm filtration.  AIP was detected directly from spent media filtrate using 
LC-MS.   
To conduct LC-MS analyses, a 7 μL injection of each sample was eluted from the 
column (Acquity UPLC BEH C18 1.7µm, 2.1 × 50 mm, Waters Corp.) at a flow rate of 
0.3 mL/min using the following binary gradient with solvent A consisting of water 
(Optima LC/MS grade) with 0.1% formic acid additive and solvent B consisting of 
acetonitrile (Optima LC/MS grade) with 0.1% formic acid additive. The gradient initiated 
at 90:10 (A:B) and increased linearly from 0.0-8.0 min to 40:60 (A:B), followed by an 
isocratic hold at 40:60 (A:B) from 8.0-8.5 min, gradient returned to starting conditions of 
90:10 (A:B) from 8.5-9.0 min, and was held at this composition from 9.0-10 min.   
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Mass spectra were collected using two scan events.  The first scan event was a 
positive mode full scan with a mass range from 300 – 2000 and a resolution of 70,000.  
The second scan event was positive mode selected ion monitoring for the calculated mass 
of the predicted/identified AIP with an isolation window of 1 amu.  Predicted m/z values 
were determined by using the known AgrD sequence as a guide.  Starting with an initial 8 
residue sequence, amino acid residues were added and subtracted from the N-terminus.  
The mass spectrometer was operated using a heated electrospray ionization source with 
the following setting: capillary temperature set at 300°C, S-Lens RF level set at 80, spray 
voltage set at 4.0 kV, sheath gas flow set at 50 (arbitrary units), and auxiliary gas flow set 
at 15. 
2.2.3.1 Confirmation of Listeria monocytogenes AIP 
Confirmation of correct AIP identification was achieved through MS-MS 
analysis.  The calculated AIP m/z value, 699.29985, was selected as precursor ion and 
subjected to high-energy collision dissociation (HCD) at normalized collision energy of 
23.  Resulting spectra were compared to predicted fragmentation pattern of AIP ion.  
Fragmentation prediction was performed on ACD Labs fragment predictor. 
2.2.3.2 Confirmation of Staphylococcus saprophyticus AIP 
 Confirmation of correct AIP identification was achieved through MS-MS analysis 
using a Thermo Fisher LTQ Orbitrap XL Hybrid Ion Trap-Orbitrap mass spectrometer 
coupled to an Aquity UPLC system using the same instrument settings listed above.  
Calculated AIP m/z value, 896.39764, was selected as precursor ions and subjected to 
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collision induced dissociation (CID) at normalized collision energy of 35.  Resulting 
spectra were compared to predicted fragmentation pattern of AIP ion. 
2.2.4 Ambuic Acid Inhibition Assays 
 Assays to evaluate inhibition by ambuic acid were performed in a 96-well plate 
format. Overnight cultures were diluted 1:200 (culture:broth) and shaken (200 rpm) at 37 
°C for two hours.  An aliquot of this culture (200 μL)  was then combined with 45 μL 
broth and 5 μL dimethyl sulfoxide (DMSO) containing ambuic acid  (Adipogen 
International, San diego, CA) in concentrations ranging from 20 μM to 10 mM prepared 
in two-fold serial dilutions.  Final ambuic acid concentration in the assay wells ranged 
from 390 nM to 200 μM.  Plates were shaken at 1000 rpm at 37 °C using a Stuart S1505 
microtitre plate shaker (Bibby Scientific Limited, Staffordshire, U.K.).  Cell growth was 
monitored by measuring absorbance at 600 nm at one hour intervals.  Cells were grown 
to the end of the log-phase and were removed via vacuum filtration.  Filtrate was 
analyzed using LC-MS method described above.  Selected ion chromatograms for the 
identified AIP m/z values were plotted and peak area values were used for relative AIP 
concentration comparison.  IC50 values were determined from a four parameter logistic 
function using Sigma plot 12.5. 
2.3 Results 
2.3.1 Identification of AIPs  
Using the hybrid quadrupole-Orbitrap mass spectrometer in combination with 
published gene sequence data, it was possible to identify AIPs directly from spent media 
of bacterial cultures. The method was applied to detect and sequence AIPs from 
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Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, and 
Enterococcus faecalis.  Results agreed with reported data for S. aureus [39, 41, 49], S. 
epidermidis[44], S. lugdunensis [49], and E. faecalis [42], strains for which AIPs have 
previously been reported, and were also used to identify unknown AIPs in Listeria 
monocytogenes and Staphylococcus saphrophyticus.   
Identification of the L. monocytogenes AIP was enabled by detection of an ion 
with m/z of 699.29910 in spent media.  This value corresponded to the cyclic hexapeptide 
Ala-c(Cys-Phe-Met-Phe-Val) containing a thiolactone ring linked between the sulfhydryl 
group of the cysteine and the α-carboxyl group of the C-terminal valine (calc. m/z 
699.29985, mass error 1.5 ppm).  For S. saphrophyticus, an ion with m/z 896.3971 was 
identified.  This value corresponded to the cyclic octapeptide Ile-Asn-Pro-c(Cys-Phe-
Gly-Tyr-Thr) containing a thiolactone ring linked between the sulfhydryl group of the  
cysteine and the α-carboxyl group of the C-terminal threonine (calc. m/z 896.39764, mass 
error of 2.6 ppm).  Identified ions were subjected to fragmentation and the resulting 
product ions were in agreement with the predicted fragmentation patterns for these 
peptides (Figures 5 and 6). 
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Figure 5.  Identification of Listeria monocytogenes AIP. 
Structure, sequence and accurate mass of the [M+H]
+
 ion for the identified L. 
monocytogenes AIP are shown in panel A.  Selected-ion chromatogram for m/z 
699.2998 (B) was used to detect AIP, and higher-energy collision dissociation 
(HCD) MS-MS fragmentation pattern of the ion with retention time of 5.81 min 
and m/z of 699.3015 (C) was used to confirm correct identification.  In panel C, 
the purple peak is unfragmented precursor ion, the blue peak is representative a 
water loss, and the green peaks match within 3 ppm mass error of predicted 
fragment ions. 
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Figure 6.  Identification of Staphylococcus saphrophyticus AIP. 
Structure, sequence and accurate mass [M+H]
+
 for the identified S. saphrophyrius 
AIP are shown in panel A.  Selected-ion chromatogram for m/z 896.3976 (panel B) 
was used to detect AIP, and collision-induced dissociation (CID) MS-MS 
fragmentation pattern (C) was used to confirm correct identification.  Blue peak is 
representative a water loss, red peak matches the expected m/z for the y7 fragment, 
yellow peak matches the expected m/z for the y6 fragment, and the green peak 
matches the expected m/z for the y6 fragment. 
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2.3.2 Quantification of AIP 
Once the identification of all AIPs was confirmed, the peak area for the relevant 
AIP ion could be monitored to compare AIP production under different treatment 
conditions.  Known agr system inhibitors of S. aureus were tested against a clinical 
isolate of methicillin-resistant Staphylococcus aureus (USA300 LAC strain, AH1263) 
strain (Figure 7), and the resulting chromatographic peak corresponding to AIP I was 
significantly (p < 0.001) reduced compared to the untreated control, indicating AIP 
inhibition could be directly monitored via LC-MS.  Ambuic acid, a known AgrB inhibitor 
[50] discussed in more detail in Section 2.3.3, was tested in varying concentrations to 
determine if the described method could detect the decreasing concentration of AIP in a 
dose dependent manner.  The resulting selected-ion chromatograms (Figure 8) represent 
AIP concentration decreasing as the concentration of the inhibitor increases.  The peak 
area of the selected-ion chromatogram for m/z 961.3799 (AIP-I) was plotted against the 
concentration of ambuic acid, resulting in a dose-response curve from which an IC50 
value could be determined (Figure 9).  
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Figure 7.  Inhibition of S. aureus Agr System. 
Selected-ion chromatograms (m/z 961.3788) obtained by LC-MS analysis of the 
spent broth from a culture of the clinical MRSA USA300 LAC strain (AH1263).  
The chromatogram for the strain grown without the agr system inhibitor (A) is 
compared to chromatograms of the strain grown with 50 μM of an AgrB inhbitor 
(ambuic acid) (B), and with 4.5 μM of an AgrC inhibitor (AIP II) (C). 
 
A. 
B. 
C. 
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Figure 8.   Inhibition of AIP Production by MRSA (AH1263) with Ambuic Acid 
Selected-ion chromatograms (m/z 961.3799) showing a decreasing peak area for 
AIP in response to an increasing concentration of ambuic acid in the growth 
media.  Concentration of ambuic acid from A to H: 0 μM, 0.39 μM, 0.78 μM, 1.6 
μM, 3.1 μM, 6.3 μM, 13 μM, 25 μM.  RT indicates the retention time, AA 
indicated the peak area and BP indicates the observed m/z value for the 
chromatographic peak.  
D. 
A. 
B. 
C. 
E. 
F. 
G. 
H. 
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Figure 9.  Dose-Response Curve for Ambuic Acid 
Dose-response curve for peak area of AIP as a function of ambuic acid 
concentration.  Curve fitting was accomplished using a four parameter logistic 
equation in Sigma Plot 12.  
 
2.3.3 Broad Applicability of Ambuic Acid as a Quorum Sensing Inhibitor 
 A number of S. aureus agr system inhibitors have previously been identified in 
literature [33-36, 40, 50-52], including the small molecule fungal metabolite ambuic acid.  
Nakayama et. al. suggested that ambuic acid should be broadly applicable against 
multiple strains of Gram-positive bacteria, and provided some data indicating inhibition 
of AIP production by ambuic acid against Enterococcus faecalis, Staphylococcus aureus 
and Listeria innocua.  Using the method developed herein, we expanded these studies to 
compare IC50 values for ambuic acid against multiple bacterial strains, four species of  
Staphylococci (S. aureus, S. epidermidis, S. lugdunensis, and S. saprophyticus), Listeria 
monocytogenes and E. faecalis.  Inhibition against three agr types of S. aureus (type I-III) 
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and three agr types of S. epidermidis (type I-III) was also evaluated. Table 3 shows the 
IC50 values determined for the various bacterial strains.  The IC50 for AIP inhibition by 
ambuic acid was less than 25 µM in 8 of the 11 strains tested in this study, with the most 
potent inhibition observed against E. faecalis (IC50 1.8 ± 0.7 µM).  Surprisingly, very 
little inhibition was observed for S. lugdunensis agr type I and S. epidermidis agr types II 
and III (IC50 values greater than 200 µM). 
Table 3.  IC50 Values for Ambuic Acid Inhibition of AIP Biosynthesis 
Strain ID Species Agr Type IC50 (µM) AIP Sequence 
AH3335 E. faecalis N/A 1.8 ± 0.7 QNSPNIFGQWM
a 
LS1 L. monocytogenes N/A 8.7 ± 0.2 ACFMFV
a 
AH1263 S.aureus Type I 2.5 ± 0.1 YSTCDFIM
a 
AH2623 S.aureus Type II 23.6 ± 3.5 GVNACSSLF
a 
AH759 S. aureus Type III 10.1 ± 0.3 INCDFLL
a 
4804 S. epidermidis Type I 15.1 ± 2.8 DSVCASYF
a 
5183 S. epidermidis Type II >200  NASKYNPCSNYL
a 
5794 S. epidermidis Type III >200 NAAKYNPCASYL
a 
AH2160 S. lugdunensis Type I >200 DICNAYF
a 
AH2776 S. saprophyticus N/A 2.6 ± 1.5 INPCFGYT
a 
a Residues indicated with red form the thiolactone or lactone ring with the c-terminus.  
2.3.4 Growth Effects 
 AIP is produced in a density dependent manner, meaning higher cell density 
yields higher AIP concentration.  For this reason, any growth inhibition can easily be 
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misinterpreted as agr system inhibition.  In order to rule out this confounding factor, cell 
growth was monitored by collecting OD600 readings at 1 hr intervals leading up to the 
final AIP measurement for each experiment.  Inspection of the resulting growth curves 
demonstrated no significant growth inhibition by ambuic acid at concentrations below 
200 µM for any of the strains tested in this study, as demonstrated by the representative 
growth curve in Figure 10.  Growth inhibition was observed at concentrations above 200 
µM, so AIP inhibition was not evaluated above this concentration. 
 
Figure 10.  Growth Curve for S. aureus Agr Type I with Ambuic Acid 
Evaluation of growth effect for the varying concentrations of ambuic acid was 
accomplished by the comparison of growth curves.  Ambuic acid was tested at 
concentrations ranging from 0 μM to 100 μM over a 7 hr time period.  No growth 
effects were observed for these concentrations of ambuic acid. 
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2.4 Discussion 
The present study utilizes the ability to detect and quantify AIP in the complex 
growth media of a bacteria culture to provide insight into agr system activity.  Knowing 
the correct AIP structure for a species of bacteria is also a valuable tool for studying a 
wide range of cellular functions.  This study focused primarily on the link between the 
agr system and virulence, however the agr system has also been linked to biofilm 
formation, an important mechanism in antibiotic resistance [39].  Current methods for 
monitoring agr system activity rely on either colorimetric responses [51], which can be 
difficult to accurately quantify, or luminescence/fluorescent methods [33, 50, 53], which 
require genetically modifying the organism of interest and are potentially susceptible to 
interference in complex matrixes.  The method developed herein requires only knowledge 
of the AIP structure, and allows for the direct monitoring of the agr system of the 
organism of interest, making it applicable to clinically relevant strains of bacteria.  Using 
the developed method, an IC50 value for ambuic acid was determined against a variety of 
Gram-positive bacteria.  While ambuic acid has been previously identified as an agr 
system inhibitor, no IC50 values for this compound have been reported. 
 It is interesting to note that two of the three strains that showed little response to 
treatment with ambuic acid were strains of S. epidermidis, a human commensal of the 
skin and mucosal surfaces.  S. epidermidis may help inhibit the colonization of more 
pathogenic bacteria, such as S. aureus [54-56].  Therefore, it might be advantageous to 
inhibit the agr system of more pathogenic bacteria while leaving some S. epidermidis 
strains functioning normally.  The observation that ambuic acid doesn't inhibit two of the 
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three agr types of S. epidermidis may offer further insight into ambuic acid’s mode of 
action, and could be the topic of future studies. 
2.5 Conclusion 
 Anti-virulence has proven to be a promising method for combating bacterial 
infections in animal models [33, 35], and the agr system is an ideal target for inhibiting 
virulence in a wide variety of Gram-positive bacteria.  The presented study utilized the 
technological advances in mass spectrometry as a basis for broadly applicable method for 
monitoring agr system activity.  We presented the structure of two new AIPs, S. 
saprophyticus and L. monocytogenes, and used our newly developed method to measure 
the IC50 values of ambuic acid inhibition against a variety for Gram-positive bacteria.  
Our results demonstrate the potential usefulness of ambuic acid as a broad spectrum agr 
system inhibitor. 
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CHAPTER III 
DEVELOPMENT OF A BIOASSAY TARGETING AIP BIOSYNTHESIS 
3.1 Introduction 
 The past four decades of drug discovery have been marked by a drastic decline in 
antibiotic discovery, with only 2 new classes of antibiotics discovered since 1968 [4].  
Unfortunately, this time period also saw a rapid increasing presence of antibiotic resistant 
bacteria [1], leading some healthcare professionals to believe we are rapidly approaching 
a “post-antibiotic” era.  While the discovery of new antibiotics may aid in the continual 
fight against bacterial infections, it is imperative to identify new therapeutics that 
function through novel mechanisms of action. 
Quorum sensing is used by bacteria to regulate numerous cellular functions.  In 
Gram-positive bacteria, the quorum sensing agr system has been linked to the production 
of virulence factors [37, 39, 40, 44, 57].  This makes the agr system an ideal target for 
therapeutics capable of combating bacterial infections.  Previous research has proven the 
viability of targeting the agr system in Staphylococcus aureus to fight off these infections 
[33-36, 39, 40, 51, 57, 58], and the common presence of the agr system throughout a 
variety of Gram-positive bacteria [39] shows the possibility of the agr system to serve as 
a broad-spectrum target. 
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The agr system is comprised of two primary regions, a two-component regulatory 
cascade and a signal biosynthesis region.  The two-component regulatory cascade 
consists of AgrC, an integral membrane sensor, and AgrA, a response regulator.  The 
signal biosynthesis region contains AgrB, a membrane-bound peptidase, and AgrD, a 
propeptide to the agr system activator AIP [36, 39] (Figure 4).  Currently, the majority of 
published agr system inhibitors target the regulatory cascade region of the agr system 
[34].  While most of these studies focus on competitively inhibiting AgrC [51, 59, 60], 
some have identified molecules capable of inhibiting AgrA [33, 61, 62].   Unfortunately, 
AgrC may not be the ideal target for a broad-spectrum quorum sensing inhibitor due to 
the high variability in its sequence throughout different bacterial species [39] and its 
propensity to be hypermutable [34, 63].  AgrB, however, is relatively conserved 
throughout most species of Gram-positive bacteria [39] and spans across the cytoplasmic 
membrane. Therefore, the AIP biosynthesis region may be an ideal target for broad-
spectrum quorum sensing inhibition. 
Nakayama et. al. identified the small molecule fungal metabolite ambuic acid as 
an inhibitor of the fsr system in Enterococcus faecalis an analogous agr system.  Their 
study suggested inhibition of FsrB (AgrB analog) as the mode of action for this 
compound.  This conclusion was based on their observation that, when treated with 
ambuic acid, the Fsr system was inactive but could be reactivated with the addition of 
synthetic GBAP (an AIP analog) [50].  Additional studies performed in our laboratory 
(Chapter I) showed the potential of ambuic acid to act as a broad-spectrum agr system 
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inhibitor, confirming that the AIP biosynthesis region of the agr system is viable target 
for broad-spectrum quorum sensing inhibition.   
Ambuic Acid is currently the only known AIP biosynthesis inhibitor.  The 
purpose of this study was to develop a novel biological assay to specifically screen for 
new AIP biosynthesis inhibitors.  The Horswill lab at the University of Iowa (Iowa City, 
IA), engineered a strain of S. aureus to contain only the genes that encode for AgrB and 
AgrD.  The resulting strain continuously produced AIP unless inhibited by a compound 
specifically targeting AIP biosynthesis.  By combining the previously established method 
for efficiently quantifying AIP production (Chapter I) with this newly developed strain of 
S. aureus, complex mixtures and pure compounds could be rapidly evaluated for their 
ability to inhibit AIP biosynthesis.  This method has allowed us to efficiently screen over 
500 natural product compounds, as well as confirm ambuic acid's mode of action.   
3.2 Materials and Methods 
3.2.1 Instrumentation 
 Optical density readings were performed using a Synergy H1 Mutli-Mode Reader 
(Biotek Instruments, Inc., Winooski, VT).  Liquid chromatography-mass spectrometry 
(LC-MS) was performed using an Aquity ultra-high performance liquid chromatography 
(UPLC) system (Waters Corporation, Milford, MA) coupled to a Q Exactive Plus Hybrid 
Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA).  
Unless otherwise stated, all solvents used for chemical analyses were purchased from 
Thermo Fisher Scientific (Waltham, MA) 
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3.2.2 Bacterial Strains, Media and Growth Conditions 
 The Horswill lab at University of Iowa, Iowa City, Iowa, provided all bacteria 
strains used in this study (Table 4).    
Table 4.  Bacteria Strains 
Strain Description Reference 
AH1263 Erm-sensitive CA-MRSA USA300-0114 [64] 
AH1292 AH1263 Δagr::TetM [65] 
AH2989 AIP Constitutively Producing Strain This work 
 
3.2.3 Engineering of AIP Constitutively Producing Strain (AH2989) 
 Strain AH2989 was constructed in a series of steps.  Initially, the sarA P1 
promoter was amplified by PCR from the AH1263 genome using oligonucleotides 
ARH120 (5’-GTTGTTAAGCTTCTGATATTTTTGACTAAACCAAATGC-3’) and 
CLM607 (5’ -CACCACTCTCCTCACTGTCTCTAGAGATGCATCTTGCTCGATACA 
TTTG-3’).  The PCR product was purified, digested with HindIII and XbaI, and cloned 
into plasmid pLL29 [66].  Next, the agrBD genes from AH1263 (agr type I) were 
amplified by PCR using CLM608 (5’-TCTAGAGACAGTGAGGAGAGTGGTGTAAA 
ATTG -3’) and CLM606 (5’-GTTGTTGAATTCCTATTTAAATTATTCGTGTAATTG 
TG-3’).  The PCR product was purified, digested with XbaI and EcoRI, and cloned into 
pLL29 downstream of the sarA P1 promoter.  Plasmid pLL29 with the sarA P1 promoter 
driving agrBD was integrated into RN4220 using the protocol previously described [66].  
The integrated construct was crossed by 80α phage transduction into AH1263 by 
selecting for tetracycline resistance.  The Δagr::TetM construct was subsequently crossed 
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from AH1292 into this strain by selecting for minocycline resistance, which is conferred 
by the TetM marker.     
3.2.4 Pure Compounds for Screening 
 A natural products library containing 144 compounds was purchased from 
Selleckchem (Houston, TX).  The Oberlies lab at the University of North Carolina 
Greensboro provided an additional 426 natural product compounds.  The positive control 
ambuic acid was purchased from Adipogen International, San diego, CA. 
3.2.5 Screening for AIP Biosynthesis Inhibitors 
Bacteria cultures were prepared as previous described in Section 2.2.3. 
Samples dissolved in 1:1 dioxane:methanol were aliquoted into a 96-well plate 
with 1 mL wells. 10 µL of sterilized glycerol was added to each well, and the 96-well 
plate was vacuum concentrated for 1.5 hr to facilitate the removal of dioxane:methanol.  
Dimethyl sulfoxide was added to each well until final sample concentration was 1.25 mM 
per well.  Sample (5 μL) was combined with 45 µL of TSB and 200 µL of 2 hr bacteria 
culture in a 200 µL clear bottom 96-well plate, resulting in a final sample concentration 
of 25 µM per well. For the first stage of screening samples were tested in a single well.  
Samples moved forward to the second stage of screening were tested in triplicate.  A 
vehicle control was prepared by subjecting a blank aliquote of 1:1 dioxane:methanol to 
all previously described steps.  Ambuic acid was used as a positive control, and both 
negative and positive controls were analyzed in triplicate (biological replicates) with 
every assay.    
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The plate was shaken at 1000 rpm at 37 °C using a Stuart S1505 microtitre plate 
shaker (Bibby Scientific Limited, Staffordshire, U.K.) and cell growth was monitored in 
one-hour intervals using an optical density of 600 nm.  Cells were grown to the end of the 
log-phase, approximately 5 hr, and were removed via vacuum filtration.  The filtrate was 
analyzed using LC-MS. 
For the LC-MS analysis, a 7 μL injection of each sample was eluted from the 
column (Acquity UPLC BEH C18 1.7µm, 2.1 × 50 mm, Waters Corp.) at a flow rate of 
0.3 mL/min using the following binary gradient with solvent A consisting of water 
(Optima LC/MS grade) with 0.1% formic acid additive and solvent B consisting of 
acetonitrile (Optima LC/MS grade) with 0.1% formic acid additive. The gradient initiated 
at 75:25 (A:B) and increased linearly from 0.0-3.5 min to 50:50 (A:B), followed by a 
linear increase to 0:100 (A:B) from 3.5-4.0 min, gradient returned to starting conditions 
of 75:25 (A:B) from 4.0-4.5 min, and was held at this composition from 4.5-5.0 min.   
The mass spectra were collected using a positive mode selected ion monitoring 
scan event.  An m/z value of 961.3799 was selectively monitored with a 1 amu isolation 
window.  This value corresponds with the calculated m/z value for the AIP produced.  
The mass spectrometer was operated using the same parameters described in Section 
2.2.3 
3.2.6 Quantification of AIP 
 Using Thermo Fisher Scientific's Xcalibur software the selected ion 
chromatogram for m/z 961.3799 plotted and the corresponding peak area was used for 
relative AIP quantity determination.  An automatic processing method was designed to 
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facilitate rapid and consistent peak integration.  The automatic processing method utilized 
the base peak chromatogram trace with a selected m/z value of 961.3799 and a mass 
tolerance of 5 ppm. The Genesis peak detection algorithm with 7 smoothing points and a 
0.5 signal to noise threshold was used for peak integration.  A 30 sec retention time 
window was set at 2.35 min. 
3.3 Results 
3.3.1 Development of Targeted Bioassay 
 Inhibiting the quorum sensing agr system has proven to be viable mechanism for 
combating Gram-positive pathogens [33-35].  Specifically targeting AgrB has the 
implication for development of a broad-spectrum quorum sensing inhibitor.  Until now, 
no efficient method has been developed to efficiently screen for AgrB inhibitors.  In the 
present study, we use the combination of a uniquely engineered strain of S. aureus 
(AH2989) and an efficient mass spectrometry-based method for AIP detection to create a 
novel biological assay specifically designed to facilitate the discovery of new AIP 
biosynthesis inhibitors (Figure 11). 
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Figure 11.  Bioassay Workflow 
The workflow shown here allows for the rapid screening of multiple drug leads at 
one time.  A single colony bacterial culture is combined with 90 potential drug 
leads in one 96-well plate.  Positive and negative controls are analyzed in triplicate 
throughout the plate.  The OD600 is measured every hr to evaluate cell growth.  
Once the bacterial growth reaches the end of the log-phase, approximately 6 hr, 
cells are removed via vacuum filtration, and filtrate is analyzed using LC-MS. 
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3.3.2 Confirmation of Ambuic Acid's Mode of Action 
 A comparison between the observed agr system inhibition between the AIP 
constitutively producing strain (AH2989) and the USA300 strain (AH1263) was 
performed to ensure that AIP biosynthesis inhibitors would selectively inhibit the AIP 
constitutively producing strain (AH2989).  Using the workflow out lined in Figure 11, 
ambuic acid,  a compound previously proposed to act as an AIP biosynthesis inhibitor 
[50], and AIP II, the signaling molecule produced by S. aureus agr type II with the amino 
acid sequence Gly-Val-Asn-Ala-c(Cys-Ser-Ser-Leu-Phe) and known to inhibit AgrC 
[39], were tested against both strains.  Confirmation of ambuic acid’s mode of action 
could also be achieved through this experiment. 
Ambuic acid inhibited the production of AIP by the AIP constitutively producing 
strain (AH2989), indicating it does inhibit AIP biosynthesis (Figure 12).  Ambuic acid 
also inhibits AIP production in the USA300 strain (AH1263) (Figure 12).  However, AIP 
II, a known AgrC inhibitor, inhibited AIPI production by the USA300 strain (AH1263), 
but not by the AIP constitutively producing strain (AH2989).  The observation that the 
known AgrC inhibitor was unable to inhibit the production of AIP in the constitutively 
producing strain (AH2989) indicates our assay will only identify compounds capable of 
inhibiting the AIP biosynthesis region of the agr system and not those inhibiting the 
signaling cascade.  An IC50 value of 6.6 ± 1.1 µM was determined for ambuic acid 
against the AIP constitutively producing strain (AH2989). 
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Figure 12.  Comparison of Agr System Inhibition 
Selected-ion chromatograms (m/z 961.3788) AI, AII, and AIII were all collected 
from the USA300 strain (AH1263), while BI, BII, and BIII were all collected from 
the AIP constitutively producing strain (AH2989).  Chromatograms AI and BI 
were collected from uninhibited cultures, chromatograms AII and BII were 
collected from cultures grown with 50 μM ambuic acid, and chromatograms AIII 
and BIII were collected from cultures grown with 4.5 μM AIPII.   
 
3.3.3 Growth Inhibition 
 As previously discussed in Section 2.3.4, growth inhibition can cause reduced 
AIP production that can be misconstrued as quorum sensing inhibition, and it was 
important to rule out this confounding factor.  Growth was monitored by collecting OD600 
readings at 1 hr intervals leading up to the final AIP measurement for each experiment.  
Monitoring growth-curve data enabled viable leads as AgrB inhibitors to be distinguished 
from compounds that exerted their influence on AIP production due to growth effects.  
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Two types of growth effects can be observed, growth inhibition, which is indicated by a 
reduction in the endpoint OD600 (Figure 13) and a growth delay (Figure 14), which  
reduces the OD600 at various points throughout the growth curve but not at the final 24 hr 
time point.  Without monitoring OD600 at 1 hr intervals, a growth delay can easily be  
misconstrued as quorum sensing inhibition.  For this study, only compounds showing     
< 25% growth inhibition were moved through the second stage of screening.   
 
Figure 13.  Example of Growth Inhibition 
Viridicatumtoxin at 25 μM (green line) completely inhibited the growth of the AIP 
constitutively producing strain (AH2989), while ambuic acid at 100 μM (red line) 
and the vehicle control (blue line) showed no effect on growth. 
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Figure 14.  Example of Growth Delay 
Chaetoglobsin A at 25 μM (green line) decreased the growth rate of the AIP 
constitutively producing strain (AH2989), while ambuic acid at 100 μM (red line) 
and the vehicle control (blue line) showed no effect on growth. 
 
3.3.4 Natural Product Compound Screening 
 A number of natural product compounds (570) were subjected to the first stage of 
screening using our newly developed bioassay.  The results of the assay are evaluated in 
two steps.  The first step is an endpoint analysis, in which the endpoint AIP peak area and 
endpoint OD600 for the samples are compared to the controls.  Figure 15 shows a 
representative endpoint analysis in which the bars indicate AIP peak area and the line 
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indicated OD600.  Only compounds that showed greater than 40% AIP inhibition and less 
than 25% growth inhibition were moved to the second step evaluation.  The first step 
evaluation reduced the sample size from 570 compounds down to 29.   
 
Figure 15.  Example of Endpoint Analysis 
Blue bars indicate AIP peak area and the red line indicates OD600 value (a 
measure of bacterial growth).  The ambuic acid (positive control) represents 
desired results for a lead compound (drop in AIP peak area and no effect on 
growth).  However, the majority of compounds tested (sample id), showed either 
no effect on either or had a decrease in both peak area and OD600.  Compound 
2D3, Chaetoglobsin A, appeared to be a potential lead and was subjected to 
growth curve analysis.  Figure 14, shows the resulting growth curve from 
Chaetoglobsin A and indicated decrease in AIP peak was due to growth delay. 
  
 The remaining 29 sample results were subject to the second step of the evaluation 
in which the growth curves of the compounds were compared.  Figure 16 shows a 
representative comparison of growth curves.  The second step evaluation reduced the 
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sample size from 29 compounds down to four.  The four potential leads were then 
subjected to the second stage of screening, in which all samples were evaluated in 
triplicate.  Unfortunately, upon evaluation of the second stage assay results, it was 
concluded that all AIP inhibition was due to growth effects.  An example of the second 
stage assay results can be found in Figure 17.   
 
Figure 16.  Growth Curves for Lead Compounds 
Atroviridin E, 5,6-Dihydro-9-deoxyzeaenol, Acremonidin C and Moniliphenone 
all showed a growth inhibition < 25% and an AIP inhibition > 50%, and were 
further evaluated. 
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Figure 17.  Evaluation of Acremonidin C 
Acremonidin C showed potential as a lead compound for AIP biosynthesis 
inhibition and was further evaluated in a dose dependent manner.  The endpoint 
OD600 (red line) was compared to the endpoint AIP peak area (blue bar).  It was 
concluded any AIP inhibition previously observed was a result of growth 
inhibition. 
 
3.4 Discussion 
 The development of new therapeutics capable of combating bacterial infections 
through novel mechanisms constitutes a promising strategy for addressing the problem of 
bacterial resistance.  Quorum sensing inhibition has shown promise as a possible 
mechanism for new therapeutics, and specifically targeting AIP biosynthesis has potential 
for the development of a broad-spectrum quorum sensing inhibitor.  While we were 
unable to identify any new AIP biosynthesis inhibitors from among the limited selection 
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of purified natural product compounds screened thus far, we were able to show the 
potential utility of our novel method as a screening tool for the identification AIP 
biosynthesis inhibitors, taking a valuable step in the direction of identifying new 
therapeutic agents. 
3.5 Conclusion 
 The engineered strain of S. aureus combined with measurements of AIP 
production facilitated a targeted approach that could be employed in the future for 
discovering new quorum sensing inhibitors.  Utilizing the workflow of our novel 
bioassay, we are able to efficiently narrow down large libraries of pure compounds to 
those with potential activity.  Our newly developed bioassay can now be used to continue 
screening libraries of synthetic or natural product compounds, or be utilized by natural 
product chemists in the bioactivity directed fraction process leading to the discovery of 
new lead compounds for combating bacterial infections. 
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CHAPTER IV 
INDENTIIFACTION OF AN AIP BIOSYNTHESIS INHIBITOR IN GOLDENSEAL 
(HYDRASTIS CANADENSIS) LEAF EXTRACT     
4.1 Introduction 
 Hydrastis canadensis, goldenseal, is one of the most popular herbal supplements 
used today [67-69] and is employed as a treatment for a variety of ailments ranging from 
viral and bacterial infections to intestinal disorders [70, 71].  The alkaloids commonly 
present in goldenseal extracts are well known for their antimicrobial activity [72, 73], and 
are often credited for this plant’s ability to fight bacterial infections.  However, a recent 
study performed by our lab has demonstrated goldenseal's capability to inhibit of the 
quorum sensing agr system in methicillin-resistant Staphylococcus aureus (MRSA) [74].  
The benefits of quorum sensing inhibition have previously been described in detail [34] 
and make it a very enticing mode of action for future therapeutics.  It was the goal of this 
study to investigate the mechanism of action utilized by goldenseal to inhibit the agr 
system and identify the constituents responsible for the observed activity. 
 The agr system in S. aureus is reviewed in reference [39] and an overview can be 
found in Figure 4.  While the agr system in S. aureus is most well-known, several other 
Gram-positive pathogens containing an agr system have been identified.  Inhibition of 
the agr system can occur through two pathways, inhibition of the response regulating 
cascade or inhibition of the AIP biosynthesis system.  Inhibitors of AIP biosynthesis have 
demonstrated the ability to act as broad-spectrum agr system inhibitors [50].
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Unfortunately, while a number of response regulating inhibitors [33, 51, 59-62] have 
been identified, only one AIP biosynthesis inhibitor is currently known [50].  
Identification of new AIP biosynthesis inhibitors could offer valuable insight into how 
the agr system functions, as well as provide novel compounds for drug leads.   
 The first goal of this study was to determine if goldenseal plant extract could 
inhibit the biosynthesis of AIP in S. aureus.  The second goal of this study was utilize the 
newly developed assay (Chapter III) combined with bioactivity-directed fraction (Figure 
18) to isolate new AIP biosynthesis inhibitors.  These newly identified inhibitors could 
serve as potential leads for future therapeutic development.  
 
Figure 18. Overview of Bioactivity-Directed Fractionation 
An organism of interest (plant, fungus, bacteria, etc…) is first extracted and then 
subjected to chromatographic separation.  The eluent is collected in pools and 
tested for bioactivity.  Active pools are subjected to additional chromatographic 
separation and the resulting pools tested for bioactivity.  This process is repeated 
until the active constituent can be isolated or identified. 
Separation 
Pooled Fractions 
Bioassay 
Extraction 
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4.2 Materials and Methods 
4.2.1 Preparation of a Goldenseal Extract 
 Goldenseal plant material was harvested from William Burch’s farm in 
Hendersonville, North Carolina (NC, N 35°24.277’, W 082°20.993’, 702.4 m elevation).  
A representative voucher specimen (NCU583414) was deposited in the University of 
North Carolina at Chapel Hill herbarium (NCU).  Dried plant material was macerated for 
a least 24 hr in methanol at a 5:1 ratio (mL of solvent:g of plant material).  Extract was 
separated from plant material using vacuum filtration and then concentrated using rotary 
evaporation. The methanol extract was combined with equal parts hexanes, and was 
stirred with a magnetic stir bar for at least one hr.  The phases were allowed to separate, 
and the methanol layer was removed using a separatory funnel.  The methanol layer was 
concentrated using a rotary evaporation, and was partitioned against water and 
chloroform at a 1:4:5 (methanol:water:chloroform) ratio.  Again, phases were allowed to 
separate and chloroform layer was removed.  The chloroform layer was dried using rotary 
evaporation, and served as the starting material for the subsequent experiments.  From 
this point forward, the chloroform layer will be referred to as the “goldenseal extract”. 
4.2.2 Fractionation of Goldenseal Extract 
4.2.2.1 Stages 1 and 2 of Separation 
 The first two stages of separation have been previously described in detail [75].  
In summary, the extract was loaded on a normal-phase silica column and was eluted 
using automated flash chromatography with a hexane:chloroform:methanol gradient and 
fractions were collected 1 liter increments.  A total of 9 fractions were collected, fractions 
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1-9.  The most active fraction, fraction 2, was subjected to a second stage of separation 
via flash chromatography utilizing a 120 g silica gel column (RediSep Rf, Teledyne Isco) 
and a hexane:ethyl acetate:methanol gradient over 50.3 min at a flow rate of 85 mL/min.  
The resulting fractions were pooled into 13 fractions, fractions 2A-2M, based on UV 
absorbance profile.  Bioactivity of the first two stages of separation was evaluated based 
on general agr system inhibition and method has been previously reported [75]. 
4.2.2.2 Stage 3 of Separation 
 The most active fraction, fraction 2C, was test for AgrB inhibition using 
previously described bioassay (Chapter II).  This fraction was active, and therefore was 
subjected to a third stage of normal-phase chromatography utilizing a 120 g silica gel 
column (RediSep Rf, Teledyne Isco) and a hexane:ethyl acetate:methanol gradient over 
45.2 min at a flow rate of 100 mL/min.  Resulting fractions were pooled into 13 pooled 
fractions, fractions i-xiii, and tested for AIP biosynthesis inhibition (Chapter III).   
4.2.2.3 Preparative HPLC 
 Pooled fractions ii and vii were further purified using reverse-phase preparative 
HPLC.  Samples were eluted from a Gemini-NX 5µ C-18 column (Phenomenex Inc., 
Torrance, CA) at a flow rate of 21 mL/min using a binary solvent system of acetonitrile 
(solvent A) and 0.1% acetic acid (solvent B).  For fraction ii, the gradient initiated with a 
five minute isocratic hold at 20:80 (A:B), increased linearly over 20 minutes from 20% A 
to 100% A, and was held isocratically for 5 min. 48 fractions were collected and pooled 
into 14 pools based on UV absorbance.  Pools were tested for bioactivity. 
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 For fraction vii, the gradient initiated with a five minute isocratic hold at 40:60 
(A:B), increased linearly over 50 min from 40% A to 90% A, followed by a 100% A 
column flush for 10 min.  There were 72 fractions collected and pooled into 27 pools, a-
aa, based on UV absorbance.  Pools were tested for bioactivity and pool i (showing 57% 
inhibition) was the most active.   
 Pool i yielded 2.24 mg of material, and was subjected to additional purification 
using a Synergi 4µ Max-RP column at a flow rate of 4.72 mL/min.  The gradient initiated 
with a 5 min isocratic hold of 30:70 (A:B), increased to 40% A over 0.1 min, increased 
linearly from 40% A to 50% A over 20 min, and column was flushed with 100% A for 10 
minutes.  A total of ten fractions were collected and pooled into 8 pools.  Pool 4 eluted 
from the column between 14.00-19.09 min, and yielded 1.01 mg of 80% pure material (1) 
at 16.1 min.  All other fractions were too complex and low yielding to identify 
constituents. 
4.2.3 Identification of 8-Oxotetrahydrothalifendine 
 Pooled fraction 4 was analyzed using liquid chromatography-mass spectrometry 
(LC-MS) performed on an Aquity ultra-high performance liquid chromatography (UPLC) 
system (Waters Corporation, Milford, MA) coupled to a LTQ Orbitrap XL hybrid mass 
spectrometer (Thermo Fisher Scientific, Waltham, MA).  An ion with an m/z value of 
340.1172 and UV λmax 200, 216, 293 nm was identified as the primary constituent of this 
pool.  These values corresponded to a previously identified constituent of goldenseal, 8-
oxotetrahydrothalifendine (calc. m/z 340.1185, reported UV λmax 207, 217, 291) [76].  A 
sample of compound 1 (purity >90%) was reisolated from a second batch of H. 
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canadensis leaves, and identity was confirmed using LC-MS and 
1
H NMR obtained using 
a JOEL ECS 400 MHz NMR spectrometer.  
4.2.4 AIP Biosynthesis Inhibition Assay 
 The isolated 8-oxotetrahydrothalifendine (purity > 90%) was tested for AIP 
biosynthesis inhibition using a previously described bioassay (Chapter II).   Briefly, an 
overnight culture of AIP constitutively producing strain (AH2989), see Chapter III, was 
diluted 1:200 (culture:broth) and shaken (200 rpm) at 37 °C for two hr.  The bacteria 
culture (200 μL) was combined with 45 μL broth and 5 μL dimethyl sulfoxide (DMSO) 
containing 8-oxotetrahydrothalifendine in concentrations of 500 μM and 5 mM.  Final 
concentration of 8-oxotetrahydrothalifendine in culture was 10 µM and 100 μM, 
respectively.  Cultures were shaken at 1000 rpm at 37 °C using a Stuart S1505 microtitre 
plate shaker (Bibby Scientific Limited, Staffordshire, U.K.).  An optical density of 600 
nm was used to monitor cell growth at one hr intervals.  Cells were grown to the end of 
the log-phase and were removed via vacuum filtration.  Filtrate was analyzed using LC-
MS parameters described in 2.2.4.  Selected ion chromatograms for m/z value 961.3788 
were plotted and peak area values were used for relative AIP concentration comparison. 
4.3 Results 
 The fourth round of bioactivity-guide fractionation of the goldenseal extract 
resulted in two active fractions (fractions ii and vii) with an inhibition of 56% and 41% 
respectively (Figure 19).  Further evaluation of fraction ii showed the observed decrease 
in AIP production was due to growth inhibition, and therefore no further experiments 
were pursued with this fraction.  However, fraction vii showed no significant growth 
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effect and was further purified (Figure 20), resulting in the identification of 8-
oxotetrahydrothalifendine (1) as an AIP biosynthesis inhibitor.  This compound has 
previously been identified as a constituent of goldenseal [76], however, no bioactivity has 
been reported.  Compound 1 was re-isolated from a scaled up extract, and a comparison 
of the accurate mass LC-MS chromatograms for the purified 8-oxotetrahydrothalifendine, 
fraction i, and the final pool 4 confirmed the correct compound was re-isolated (Figure 
21). 
 
Figure 19.  Bioactivity of Fractions i-xii 
Fractions i-xii were tested for AIP biosynthesis inhibition.  The vehicle control (V) 
consisted of 2% DMSO in broth.  The most active fractions, ii and vii, were 
subjected to additional purification steps. 
  
 
 
Figure 20.  Bioactivity of Fractions a-aa 
Fractions a-aa, collected from fraction vii, were tested for AIP biosynthesis inhibition.  Ambuic acid (50 μM) was used 
as a positive control (+) to ensure proper biological response was being observed, and fraction vii (the starting material) 
was tested to ensure activity wasn’t lost. 
 
5
6 
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Figure 21.  Confirmation of 8-Oxotetrahydrothalifendine in Fractions. 
The base peak chromatograms for fraction i (A), pool 4 (B), and purified 8-
oxotetrahydrothalifendine (C) indicating 8-oxotetrahydrothalifendine as the 
primary constituent of the active fractions.  Indicated on each chromatogram is the 
retention time for the observed peak and the m/z value observed at that time.  The 
signal intensity used for normalization (NL) is also indicated in the upper right 
corner of each chromatogram. 
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 Previously published 
1
H NMR shifts for 8-oxotetrahydrothalifendine [77] and the 
calculated accurate mass (m/z 340.1185) were used to confirm the identity of compound 1 
(Table 5).  8-oxotetrahydrothalifendine displays very weak potency (IC50 >100 µM) 
(Figure 22) as an AIP biosynthesis inhibitor, however, it is only the second known 
compound to inhibit the agr system through this unique mode of action.  The 
identification of this compound may help provide valuable insight into the agr system, as 
well as serve as template for future drug design. 
Table 5.  Comparison of Experimental and Literature NMR Values for 8-
Oxotetrahydrothalifendine 
Position 
δH, M (J in Hz) 
experimental 
δH, M (J in Hz) 
literature [77] 
1 6.65 6.67 
4 6.67 6.68 
5 ax 2.90 (13.9,11.1) 2.89 (15,11,3) 
5 eq 2.75 (14.9,3.3,2) 2.75 (15,3,2) 
6 ax 2.94 (12.1,11.5,2.5) 2.95 (12.5,11,2.5) 
6 eq 4.95 (m) 4.97 (m) 
11 7.06 (8.2) 7.07 (8) 
12 6.89 (8.2) 6.90 (8) 
13a 3.00 (15.3,3.4) 3.02 (15.5,3) 
13b 2.85 (15.2,13.6) 2.84 (15.5,13.5) 
14 4.72 (13.3,2.8) 4.73 
OMe 3.99 4.01 
OH 6.03 6.03 
O-CH2-O 5.95 5.96 
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4.4 Discussion 
 Previously published studies have demonstrated capability of a goldenseal extract 
to inhibit the agr system in S. aureus [74], and it was the goal of this study to further 
investigate this inhibition and identify the active constituents.  While goldenseal extract 
 
Figure 22.  Bioactivity of 8-Oxotetrahydrothalifendine. 
AIP peak area is represented by the blue bars, and OD600 is represented by the red 
line.  Ambuic acid was used as a positive control that shows AIP biosynthesis 
inhibition while having no effect on growth.  Since the AIP constitutively 
producing strain (AH2989) was used for screening, AIP II, a known AgrC 
inhibitor, should have no effect on the AIP production.  8-
Oxotetrahydrothalifendine was tested for AIP biosynthesis inhibition at two 
concentrations (10 µM and 100 µM).  While 10 µM showed no inhibition, 100 µM 
8-oxotetrahydrothalifendine inhibited AIP biosynthesis by 49% (*p < 0.001).   
* 
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may inhibit the agr system through multiple modes of action, our newly developed 
bioassay (Chapter II) showed it does, in part, work through the inhibition AIP 
biosynthesis.  This mode of action is very unique, with only one known AIP biosynthesis 
inhibitor previously published [50].  Importantly, signal biosynthesis inhibition has the 
potential for development of a broad-spectrum therapeutic against Gram-positive 
bacterial pathogens (Chapter I).   
Through the results presented here, we were able to identify a new AIP 
biosynthesis inhibitor, 8-oxotetrahydrothalifendine; however, the activity of this 
compound does not fully explain the AgrB inhibition observed from its initial fraction, 
fraction vii.  Unfortunately, we were unable to pursue further purification of the 
additional fractions collected due to limitations in quantity of material available for 
isolation (< 1mg).  
4.5 Conclusion 
 AgrB inhibition is a novel approach for combating Gram-positive bacterial 
pathogens, and this study shows the potential benefit of utilizing our newly developed 
targeted assay for the identification of AIP biosynthesis inhibitors.  The newly discovered 
AgrB inhibitor, 8-oxotetrahydrothalifendine, will be the subject of future studies that 
evaluate its potential broad-spectrum activity, and this compound may serve as a lead for 
the development of future anti-virulence therapeutics. 
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CHAPTER V 
CONCLUDING THOUGHTS AND COMMENTS 
 The problem of antibiotic resistant bacteria has placed a serious burden on the 
well-being of world's healthcare systems.  This has many healthcare professionals 
warning that without immediate intervention we will enter a "post-antibiotic" era, in 
which simple cuts, scraps and burns could result in deadly bacterial infections [78].  Anti-
virulence has emerged as a potential strategy for combating bacterial pathogens.  When 
tested in animal models, anti-virulence compounds have significantly reduced the effect 
of bacterial infections and have proven to be less susceptible to resistance development 
[33]. Unfortunately, while anti-virulence has shown promise as a therapeutic strategy, no 
compounds have been approved for clinical use.  The majority of agr system inhibitors 
are antagonist peptides, however, as previously stated AgrC is highly susceptible to 
mutation.  Inhibitors of the AgrA and AgrB may be the best candidates for therapeutic 
development, unfortunately only a limited number of compounds showing these actives 
have been discovered and their potency is very limited.  Thus, there is a need for 
additional therapeutic leads capable of inhibiting either AgrA or AgrB. 
The studies presented here explored the agr system and developed a new assay 
for identifying agr system inhibitors.  Chapter II presented a method for identifying and 
detecting AIP, the agr regulator, in the growth media of multiple species of bacteria.  
Using this knowledge, we were able to monitor agr system activity in each of these 
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species.  Traditional methods for monitoring agr system activity relied on the 
development of bioengineered strains of each species of bacteria to serve as a 
representative model.  Our method allows for a direct evaluation of the clinically relevant 
strain.  In Chapter III, we explored a target for broad-spectrum agr inhibition, AIP 
biosynthesis, and provided a novel screening assay for the identification of compounds 
that specifically target AIP biosynthesis.  This screening method can now be used to 
efficiently screen libraries of known compounds to discover new drug leads.  We also 
incorporated our novel screening method in to the bioactivity-guide fractionation process 
utilized in traditional natural products, Chapter IV.  This allowed us to identify 8-
oxotetrahydrothalifendine, a known constituent of the medicinal plant goldenseal, as an 
AIP biosynthesis inhibitor.  While 8-oxotetrahydrothalifendine wasn't a very potent 
inhibitor, it did validate the approach using our novel assay.  Moving forward our assay 
will be used to screen multiple pure compound and natural product extract libraries for 
potential drug leads that inhibit signal biosynthesis.  
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